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eri-Procedural Platelet Function and Platelet
nhibition in Percutaneous Coronary Intervention
ean J. Kereiakes, MD, FACC,* Paul A. Gurbel, MD, FACC†
incinnati, Ohio; and Baltimore, Maryland
re-procedural platelet reactivity has been correlated with adverse ischemic events following percuta-
eous coronary intervention. Patients with high pre-percutaneous coronary intervention platelet reac-
ivity demonstrate a differential response to standard doses of antiplatelet therapies and have higher
esidual post-treatment platelet reactivity. Peri-procedural platelet inhibition has been inversely corre-
ated with the occurrence of adverse clinical outcomes, particularly myocardial infarction. Preliminary
vidence supports the concept of a threshold for post-treatment platelet reactivity, and patients with
ess than 40% to 50% residual aggregation in response to 20-mol/l adenosine diphosphate appear to
ave the best long-term clinical outcomes. Wide interindividual variability in response to either aspirin
r clopidogrel has been demonstrated, and hyporesponsiveness to either agent has been associated
ith adverse clinical outcomes. Although the prevalence of either aspirin or clopidogrel resistance may
e reduced by increasing the dose of medication, it cannot be eliminated, and interindividual variabil-
ty in response persists. The advent of direct-acting antithrombin agents for peri-procedural anticoagu-
ation coupled with novel antiplatelet therapies on the immediate horizon promise to enhance the
afety and efﬁcacy of peri-procedural adjunctive pharmacotherapy. (J Am Coll Cardiol Intv 2008;1:
11–21) © 2008 by the American College of Cardiology Foundationg
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arterial Injury, Platelet Activation,
nd the Coagulation Cascade
uring either spontaneous or iatrogenic (percuta-
eous coronary intervention [PCI]) plaque rupture,
he arterial endothelial barrier is denuded, and
therosclerotic material, connective tissue ele-
ents, and subendothelial matrix proteins (colla-
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rant and/or research support from AstraZeneca, Schering-Plough,
anofi-Aventis, Portola, and Daiichi Sankyo; and consulting fees from
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peaker’s Bureaus of Eli Lilly & Co., Daiichi Sankyo, Sanofi-Aventis,
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anuscript received November 14, 2007; revised manuscript received
anuary 22, 2008, accepted January 25, 2008.en, von Willebrand factor) are exposed to blood.
latelets adhere to collagen and von Willebrand
actor via specific cell receptors (glycoprotein [GP]
I, GP Ia/IIa, GP Ib-IX) and become activated
1,2). Activated platelets degranulate and secrete
gonists, chemotaxins, clotting factors, and vaso-
onstrictors that promote platelet aggregation,
hrombin generation, and vasospasm. Following
latelet activation, alpha granule contents (CD40L,
D62p, intracellular GP IIb/IIIa receptor pool,
nd so on) are exposed on the platelet membrane.
ctivated platelets stimulate cytokine release and
issue factor exposure (3–5).
The interactions of adenosine diphosphate
ADP) with platelet receptors, particularly P2Y12,
nd of TXA2 with thromboxane receptors play a
entral role in transforming the GP IIb/IIIa recep-
or to an activated state. The subsequent binding of
brinogen and von Willebrand factor to activated
P IIb/IIIa receptors facilitates irreversible platelet
ggregation and clot stabilization (6). Despite
herapy with aspirin and unfractionated heparin
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112UFH), clinical and laboratory investigations have demon-
trated that the coagulation cascade is activated during
alloon angioplasty or stenting with thrombin generation
nd thrombus deposition at the site of arterial deep wall
njury (7–10). Thus, the rationale for antiplatelet therapy
uring and following PCI is to prevent thrombus formation,
o arrest procoagulant activity and inflammatory processes,
o promote platelet disaggregation, and to facilitate micro-
ascular perfusion (6).
re-Procedural Platelet Activity
aseline platelet reactivity measured directly by agonist-
timulated aggregation and surface receptor expression or
ndirectly indicated by platelet volume has been correlated
ith adverse clinical events during PCI (4,11–14). Those
atients with the most reactive platelets demonstrate the
ighest incidence of peri-procedural ischemic complications
ncluding myocardial infarction, urgent revascularization,
and stent thrombosis. Following
primary PCI for ST-segment el-
evation myocardial infarction,
those patients with the highest
pre-procedural platelet reactivity
subsequently demonstrate both
impaired microvascular reperfu-
sion as well as an increase in
adverse cardiovascular events in
the follow-up period (14,15).
Furthermore, patients with high
baseline (pre-PCI) platelet reactivity
demonstrate a differential response
to standard doses of antiplatelet
therapies and a higher residual post-
treatment platelet reactivity (16,17).
atients with unstable coronary syndromes have increased platelet
urface receptor (CD62p, GP IIb/IIIa) expression (18,19) and a
iminished inhibitory response to a standard dose of tirofiban
r clopidogrel (16,17). A similar differential response to
lopidogrel has been observed in diabetic patients who also
emonstrate baseline abnormalities in platelet size and
unction (20). Baseline platelet reactivity has also been
irectly correlated with angiographic and clinical restenosis
ollowing bare-metal stent deployment (21).
rocedural Platelet Inhibition
ata from randomized controlled clinical trials, which
valuated various classes of platelet inhibitor therapies,
upport the premise that the magnitude of peri-procedural
latelet inhibition is inversely correlated with the occurrence
f adverse clinical outcomes, especially peri-procedural
bbreviations
nd Acronyms
DP  adenosine
iphosphate
OX  cyclooxgenase
P  glycoprotein
ACE  major adverse
ardiac events
AR  protease-activated
eceptor
CI  percutaneous
oronary intervention
FH  unfractionated
eparinyocardial infarction. In the GOLD (AU-Assessing Ul- fiegra) trial, a correlation between higher levels of platelet
nhibition and enhanced clinical benefit was observed (22).
hose patients who achieved95% platelet inhibition at 10
in or 70% inhibition at 8 h following initiation of a GP
Ib/IIIa inhibitor bolus dose demonstrated the lowest prob-
bility of incurring a major adverse cardiovascular event.
rials of GP IIb/IIIa inhibitors, which achieved lower levels
f ex vivo platelet inhibition (IMPACT-II [Integrelin to
inimize Platelet Aggregation and Coronary Thrombosis
n Stenting] (23) and RESTORE [Randomized Efficacy
tudy of Tirofiban for Outcomes and REstenosis] (24)
tudies), also demonstrated a lesser magnitude of clinical
enefit (vs. placebo) as reflected by a reduction in the
omposite occurrence of death or nonfatal myocardial in-
arction through 30 days. Similarly, the greater degree of
latelet inhibition achieved by the ESPRIT (Enhanced
uppression of the Platelet IIb/IIIa Receptor with Integrilin
herapy) study’s dose regimen of eptifibatide (25) (com-
ared with the less potent IMPACT-II study’s dose regi-
en), conferred a greater relative magnitude of reduction in
dverse ischemic events (vs. placebo) in their respective
rials. Finally, in the TARGET (Do Tirofiban and ReoPro
ive Similar Efficacy Outcomes Trial) trial (26), those
atients who were randomly assigned to receive abciximab
compared with tirofiban) demonstrated a reduction in the
ccurrence of death, myocardial infarction, or urgent target
essel revascularization through 30 days (6.0% vs. 7.6% with
irofiban; p  0.038). These superior results of abciximab
ave been ascribed to higher relative levels of platelet
nhibition (27), although an effect of abciximab independent
f GP IIb/IIIa receptor inhibition cannot be excluded (28).
Thus, multiple observations support the concept of tar-
eting high levels of platelet inhibition during the perfor-
ance of PCI when GP IIb/IIIa inhibitors are used. As
latelet activation is a complex process that involves multi-
le redundant pathways (Fig. 1), therapeutic strategies that
nclude simultaneous blockade of multiple receptors (cy-
looxgenase [COX]-1 by aspirin, P2Y12 by thienopyridine,
P IIb/IIIa by GP IIb/IIIa inhibitor) are intuitively attrac-
ive and have been demonstrated to achieve incremental
nhibition of platelet activation and aggregation (29–31).
or example, those patients who were administered an oral
lopidogrel loading dose (300 mg) 2 to 6 h prior to PCI in
he TARGET trial enjoyed a significant relative reduction
n adverse primary end point events through 30 days when
ompared with patients who received no pre-PCI clopi-
ogrel loading dose, regardless of their randomly assigned
P IIb/IIIa inhibitor (abciximab or tirofiban) (32). Fur-
hermore, clopidogrel pre-treated patients demonstrated
mproved survival to the 1-year follow-up, which was most
arked among those patients who had been randomly
ssigned to peri-procedural tirofiban therapy. In the
LEAR PLATELETS (Clopidogrel Loading with Epti-
batide to Arrest the Reactivity of Platelets) and the
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113LEAR PLATELETS 1B (Clopidogrel Loading with
ptifibatide to Arrest the Reactivity of Platelets 1B) trials
31,33), a higher level of platelet inhibition was achieved
uring PCI in patients treated with the combination of
lopidogrel and eptifibatide compared with clopidogrel
reatment alone and was associated with a greater reduction
n markers of inflammation (high-sensitivity C-reactive
rotein; tumor necrosis factor-alpha) (33) as well as peri-
rocedural myocardial necrosis (creatine kinase-myocardial
and, troponin I, myoglobin) (31). Likewise, in the TOP-
TAR (Troponin in Planned PTCA/Stent Implantation
ith or without Administration of the Glycoprotein IIb/
IIa Receptor Antagonist Tirofiban) trial (34), the addition
f tirofiban to patients pretreated with aspirin and clopi-
ogrel prior to PCI reduced peri-procedural elevations in
roponin T. All of these studies suggest that the addition of
GP IIb/IIIa inhibitor to dual oral antiplatelet therapy
aspirin plus thienopyridine) during PCI provides a higher
evel of peri-procedural platelet inhibition, which in turn is
ssociated with a lower incidence of peri-procedural myocardial
nfarction (35).
Further confirmation of the “more is better” premise, as it
ertains to the magnitude of peri-procedural platelet inhi-
ition, is provided by the ISAR REACT II (Intracoronary
tenting and Antithrombotic Regimen—Rapid Early Ac-
ion for Coronary Treatment II) trial (36), in which high-
isk acute coronary syndrome patients were pretreated with
spirin and clopidogrel (600 mg) after coronary angiography
Figure 1. Mechanisms of Platelet Activation and Inhibition
Platelet activation and mechanism of action of antiplatelet agents. ADP 
adenosine diphosphate; ATP  adenosine triphosphate; CD40L  CD 40
ligand; COX  cyclooxygenase; GP  glycoprotein; PAI  plasminogen
activator inhibitor; PDGF  platelet-derived growth factor TXA2  throm-
boxane A2; vWF  von Willebrand factor. Adapted from Mehta SR, Yusuf S.
Short- and long-term oral antiplatelet therapy in acute coronary syndromes
and percutaneous coronary intervention. J Am Coll Cardiol 2003;41 Suppl
S:79S–88S.ut at least 2 h prior to PCI. At the time of PCI, patients Rere randomly assigned to treatment with either abciximab
r placebo, and all patients received concomitant intrave-
ous weight-adjusted UFH. By 30 days post-procedure,
bciximab-treated patients enjoyed a 25% relative reduction
n ischemic primary end point events (8.9% abciximab,
1.9% placebo; p  0.03). In a pre-specified subgroup
nalysis stratified by baseline (pre-PCI) troponin levels
elevated in approximately one-half of all patients) those
atients with elevated troponin levels had the greatest
agnitude of benefit from abciximab therapy (p  0.02),
lthough those with a normal baseline troponin demon-
trated little or no benefit. Of note, the major portion of
bciximab benefit was observed in patients with elevated
aseline troponin who were 70 years of age, although
atients 70 years old demonstrated no evidence for abcix-
mab benefit regardless of baseline troponin level (37). The
ack of apparent abciximab benefit for lower-risk patients in
SAR REACT II is similar to the observation made in the
recedent ISAR-REACT randomized, placebo-controlled
rial of abciximab administration following an oral clopi-
ogrel load (600 mg 2 h pre-PCI) in patients with stable
ngina where no difference in primary end point events (30
ays) between randomly assigned treatments was seen (38).
n summary, these data support the following concepts: 1)
igh levels of peri-procedural platelet inhibition should be
argeted particularly in high-risk patients; 2) incremental
evels of platelet inhibition are associated with a combina-
ion of agents that block various pathways (COX-1, P2Y12,
P IIb/IIIa); and 3) higher levels of peri-procedural platelet
nhibition are associated with better clinical outcomes.
ost-Treatment Platelet Reactivity
t has only been more recently appreciated that patients who
emonstrate higher levels of post-PCI (and post-adjunctive
harmacotherapy) residual platelet reactivity to ADP have
dverse clinical outcomes (39–42). For example, following
rimary PCI for ST-segment elevation myocardial infarc-
ion, those patients in the lowest quartile for inhibition of
DP-induced aggregation demonstrated more adverse
schemic events through the 6-month follow-up period
38). Similarly, following elective stent deployment, those
atients with higher (50%) residual ex vivo platelet aggre-
ation in response to 20-mol/l ADP had an increase in
schemic events (40–42). Indeed, patients who subse-
uently experienced stent thrombosis were clustered at or
bove the 75th percentile for residual ex vivo platelet
eactivity to either 5- or 20-mol/l ADP (41). Subsequent
tudies have confirmed the observation that despite oral
lopidogrel loading (300 mg) prior to or during PCI,
atients with higher levels of post-procedural residual plate-
et aggregation incur a higher incidence of major adverse
ardiovascular events including stent thrombosis (42,43).
ecent data suggest that those patients at greatest risk for
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114ubsequent stent thrombosis may be identified by low levels
25th percentile) of post-procedural platelet inhibition
sing a point-of-care platelet function assay (Accumetrics
erify Now) (44). Interindividual variability in platelet
nhibitory response occurs following both aspirin and clo-
idogrel treatments and has been correlated with adverse
eri-procedural and late ischemic events. Furthermore,
reliminary evidence supports the concept of a post-
reatment “threshold” of platelet reactivity, which is associ-
ted with adverse ischemic events in long-term follow-up
45,46). These studies suggest the potential utility of mea-
uring residual platelet aggregation post-PCI (pre-
ischarge) so that adjunctive pharmacotherapy at hospital
ischarge may be appropriately tailored for those patients at
igh risk for subsequent ischemic events.
ariability in Response to Aspirin
spirin specifically and irreversibly inhibits platelet COX-1
hrough acetylation of the amino acid serine at position 529,
hereby blocking arachidonic acid access to the COX-1
atalytic site through steric hindrance (47). The antithrom-
otic effects of aspirin (in addition to COX-1 blockade)
nclude antioxidant, anti-inflammatory, and antiatheroscle-
otic effects on endothelial cells and leukocytes (47). Aspirin
s a comparatively weak inhibitor of platelet function,
ecause other agonists such as ADP, collagen, or thrombin
an still activate platelets, as measured by ex vivo tests in
atients during aspirin treatment (48). The limitations of
spirin as an antithrombotic agent include its inability to
nhibit platelet adhesion or secretion; the limited inhibition
f platelet aggregation in response to ADP, thrombin, or
ollagen; and the persistence of platelet aggregation, platelet
hrombus formation, and post-angioplasty cyclic flow vari-
tion in aspirin-treated patients (47,48). In addition, aspirin
ffects are highly variable between individuals and may be
ounteracted by high shear rates or circulating epinephrine
evels.
Individual variability in aspirin response and resistance
ay be related to clinical or cellular factors as well as to
enetic polymorphisms (49). Laboratory methods for as-
essing platelet responsiveness to aspirin can be categorized
s either COX-1–specific or –nonspecific. The prevalence of
spirin “resistance” appears to vary by definition from 6%
in response to stimulation by arachidonic acid) to 29% (by
FA-100 assay) and by aspirin dosage from 36% (100
g) to 26% (300 mg) (50–52). It has been proposed
hat aspirin resistance be measured by a test that directly
ndicates persistent COX-1 activity (51). Thus, aspirin
esistance is most specifically identified by either: 1) the
etection of stable metabolites of thromboxane A2 (i.e.,
erum thromboxane B2 or urinary 11-dehydrothromboxane
2); or 2) arachidonic acid-induced aggregation. Although
rior studies have suggested that aspirin doses 81 mg mrovide equivalent inhibition of COX-1 (reduction in
XB2 production); more recent data suggest a dose-
ependent effect of aspirin on platelet function via non–
OX-1–dependent pathways at or downstream from the
ollagen (GPVI) receptor (52). Aspirin doses of 162 mg
ere required to achieve optimal inhibition of collagen-
nduced platelet aggregation. Thus, the effect of aspirin on
on–COX-1–mediated pathways may also influence its
verall antithrombotic properties. However, aspirin doses
bove 100 mg/day have not been shown to provide greater
linical benefit than lower doses and may be associated with
ore frequent bleeding complications (53,54). Aspirin re-
istance measured by various assays (including both COX-
–specific and –nonspecific) has been correlated with both
eri-PCI ischemic events (including stent thrombosis) as
ell as late (1 year) adverse cardiovascular events (55,56).
major limitation of studies evaluating aspirin resistance
as been the lack of serial platelet function measurements,
s the degree of aspirin responsiveness can fluctuate over
ime and may be affected by dose. Finally, aspirin hypore-
ponsiveness may also be associated with poor responsive-
ess to the concomitant administration of clopidogrel,
hich suggests the presence of a more generalized “high
latelet reactivity phenotype” that may be associated with an
ncreased risk for ischemic events (57–59).
ariability in Response to Clopidogrel
he active metabolites of thienopyridines (ticlopidine, clo-
idogrel, prasugrel) irreversibly bind to ADP (P2Y12) re-
eptors on the platelet, thus attenuating ADP-mediated GP
Ib/IIIa receptor activation and platelet aggregation (60).
he addition of ticlopidine or clopidogrel to aspirin and
eparin has been demonstrated to further reduce the indi-
es of procedural platelet activation (serotonin release;
-selectin expression) and the correlates of thrombin gen-
ration (fragment 1.2, thrombin-antithrombin complexes)
ollowing PCI (8,61). These findings are consistent with the
bservation of synergy between aspirin and ticlopidine for
nhibition of thrombosis and platelet procoagulant activity
61). Indeed, the combination of aspirin and ticlopidine has
roven superior to aspirin alone or the combination of
spirin and warfarin in reducing ischemic events and hem-
rrhagic complications after elective stent deployment
62,63). The basis for therapeutic conversion to clopidogrel
from ticlopidine) was largely due to enhanced safety and
olerance (64). Clopidogrel is administered orally as a
rodrug that requires conversion to active metabolites by
epatic cytochrome P450 isoenzymes. Clopidogrel “resis-
ance,” as identified by either: 1) persistent P2Y12 signaling
easured by loss of vasodilator-stimulated phosphoprotein
hosphorylation after ADP stimulation using flow cytom-
try methods; or 2) ADP-induced platelet activation as
easured by turbidimetric aggregation or flow cytometric
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115ssays (46), has been observed in approximately 1 of out 4
range 5% to 44%) individuals undergoing elective PCI
17,46). Differences in the prevalence of resistance between
tudies may be related to differences in clopidogrel dosing,
ifferences in definition of resistance, laboratory methods,
r the timing of blood sampling relative to clopidogrel
dministration (5,17,46). Clopidogrel response variability
as multiple proposed etiologies that include variability in
ntestinal absorption, CYP3A4 enzymatic activity (due to
enetic polymorphisms or drug–drug interactions) and
2Y12 receptor density (65–68). Platelet responsiveness to
lopidogrel as measured by turbidimetric aggregometry or
ow cytometry after ADP stimulation follows a normal,
ell-shaped distribution (Fig. 2) (17). Following a 300-mg
ral clopidogrel loading dose and 75 mg administered daily
hereafter, “resistance” was observed in 31% and 15% of
atients at 5 and 30 days post-PCI, respectively (17).
Studies have described an attenuated response to clopi-
ogrel by either relative or absolute inhibition (absolute
hange in aggregation from baseline). Both early (30 days)
nd late (30 days to 1 year) stent thrombosis or other major
dverse cardiac events (MACE) have most often been
orrelated with post-treatment platelet reactivity (40–43)
ather than with the degree of inhibition (39). Thus, either
on-treatment” or “post-treatment” residual platelet reactiv-
ty may be a better indicator of patient risk for post-stenting
schemic events because risk may be overestimated in
onresponsive patients who begin with low pre-treatment
latelet reactivity (69). However, none of these studies have
een definitive, and most are limited by small numbers of
atients and an absence of serial platelet function measure-
Figure 2. Response Distribution to Clopidogrel
Normal distribution of the absolute change in 20-mol/l adenosine di-
phosphate (ADP)-induced aggregation (∆A). All of the patients under the
double-headed arrow meet the deﬁnition for nonresponsiveness (NR). The
distribution is shifted rightward in the 600-mg group indicating greater
inhibition (responsiveness to clopidogrel). Reproduced with permissiond
from the American College of Cardiology (72).ents. In general, those patients who manifest laboratory
esistance or high post-treatment platelet reactivity incur an
ncreased incidence of MACE. In this context, the admin-
stration of larger (300 mg) oral loading doses of clopi-
ogrel has been demonstrated to accelerate the time course
nd enhance the magnitude of subsequent platelet inhibi-
ion as well as reduce platelet reactivity (70–72). Debate
emains regarding the ability of 900 mg of clopidogrel to
urther augment platelet inhibition compared with 600 mg
70,71). Although some have demonstrated more rapid and
omplete platelet inhibition with the higher dose when
easured in response to a more potent (20-mol/l ADP)
gonist, others have reported no appreciable differences in
ither measured platelet inhibition or clopidogrel metabolite
oncentrations, suggesting the potential for saturation in the
bility to either absorb or convert the increased dose.
evertheless, a 600-mg clopidogrel load is associated with a
ower prevalence of early resistance (8%) compared with a
00-mg load (25% to 28%) (72). Furthermore, the ad-
inistration of a 600-mg loading dose to individuals on
hronic clopidogrel therapy (75 mg daily) also provided a
ubstantial increment in peri-procedural (PCI) platelet in-
ibition when compared with no loading dose (73). Even
ollowing a 600-mg oral clopidogrel loading dose, from 2 to
h are required to achieve maximum platelet inhibitory
ffects, which remain widely variable (20% to 80%) on an
ndividual basis (70,74). Finally, data in support of an
ncremental clinical benefit associated with increased clopi-
ogrel loading dose (600 vs. 300 mg) are limited to a small
255 patients) randomized trial involving clopidogrel-naïve
atients that demonstrated a relative reduction in peri-
rocedural myocardial infarction following the 600-mg dose
75). However, the ARMYDA-4 (Antiplatelet Therapy for
eduction of Myocardial Damage during Angioplasty)
tudy demonstrated no additional clinical benefit following
600-mg pre-PCI clopidogrel load in patients already
eceiving chronic clopidogrel therapy (76). More recently,
ata have been presented that incremental levels of platelet
nhibition may be achieved by increasing the clopidogrel
aintenance dose from 75 to 150 mg daily, particularly in
hose patients who manifest initial hyporesponsiveness
77,78). Whether or not incremental platelet inhibition by
he 150-mg daily maintenance dose can be translated into
linical benefit (MACE reduction) without the occurrence
f adverse bleeding events remains to be determined by
arger, adequately powered clinical trials.
In addition to dosage increments to augment clopidogrel
latelet inhibition, the concomitant administration of
YP3A4 enzyme inducers (rifampin, St. John’s wort) has
een demonstrated to enhance platelet inhibition and to
onvert clopidogrel “hyporesponders” to “responders”
65,79,80). The clinical utility of adjunctive CYP3A4 en-
yme induction in clopidogrel hyporesponders has not been
emonstrated. Furthermore, the addition of a 3rd agent,
c
b
m
t
p
s
r
p
w
h
c
t
a
m
e
P
a
T
a
d
a
t

r
I
m
l
t
c
n
s
p
a
w
a
t
p
t
b
M
o
(
t
h
p
m
l
t
p
c
m
r
o
d
w
T
i
i
s
G
p
c
i
t
(
N
T
p
v
a
P
t
h
i
P
P
i
c
t
(
s
p
r
n
d
d
(
O
c
r
r
b
e
A
m
M
p
(
c
P
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 1 , N O . 2 , 2 0 0 8
A P R I L 2 0 0 8 : 1 1 1 – 2 1
Kereiakes and Gurbel
Peri-Procedural Platelet Function
116ilostazol, to patients already being treated with the com-
ination of aspirin and a thienopyridine may confer incre-
ental clinical benefit (reduction in MACE and stent
hrombosis) without an increase in bleeding events (81). As
reviously noted, the prevalence of clopidogrel hyporespon-
iveness appears to be increased among patients who are
esistant to aspirin, suggesting the presence of a “high
latelet reactivity phenotype” (57,58,82). Those patients
ho manifest an attenuated response to both agents may
ave the highest prevalence of peri-procedural (PCI) myo-
ardial necrosis (82). Interestingly, patients who are resis-
ant to clopidogrel are frequently responsive to ticlopidine
nd vice versa, which suggests that differences in liver
etabolic pathways responsible for active metabolite gen-
ration exist (83).
eri-Procedural Anticoagulation
nd Platelet Reactivity
he traditional “gold standard” for peri-procedural antico-
gulation involved the administration of weight-adjusted
oses of UFH with peri-procedural monitoring of the
ctivated clotting time and supplemental heparin adminis-
ration to achieve targeted activated clotting time levels of
250 s (in the absence of concomitant platelet GP IIb/IIIa
eceptor blockade) or 200 s (in the presence of GP
Ib/IIIa receptor inhibition) (84). Over the past decade,
ultiple limitations of UFH have been recognized. The
imitations include its inability to bind either clot-bound
hrombin or factor Xa within the platelet prothrombinase
omplex, susceptibility to inactivation by platelet factor 4,
onspecific cellular binding (which results in biphasic,
aturation kinetics and, thus, a variable dose-dependent
harmacokinetic half-life), direct platelet activation and
ggregation, as well as consumption of antithrombin III,
hich may contribute to the subsequent relative hyperco-
gulability (heparin “rebound”) following discontinuation of
herapy (85).
The central role played by thrombin in triggering
latelet activation and the ability of direct-acting anti-
hrombin agents, such as bivalirudin to inactivate clot-
ound thrombin has been more recently appreciated (86).
ultiple randomized controlled clinical trials have dem-
nstrated bivalirudin to be at least as effective and safer
fewer major bleeding events) than UFH when adminis-
ered as anticoagulation for PCI (87,88). Some studies
ave suggested that bivalirudin contributes to peri-
rocedural platelet inhibition by blocking thrombin-
ediated platelet activation. Although intravenous biva-
irudin in combination with oral aspirin and clopidogrel
herapy appears to provide safe and effective peri-
rocedural adjunctive pharmacotherapy for most clini-
ally stable patients undergoing PCI, the time course and
agnitude of antithrombotic effects achieved by this iegimen may not be adequate for patients with high levels
f pre-procedural platelet reactivity (acute coronary syn-
rome with positive biomarkers, diabetics, and so on) and
ho, in addition, may be clopidogrel hyporesponders.
hese patient subgroups may manifest a relative increase
n peri-procedural ischemic events (enzymatic myocardial
nfarction; urgent repeat revascularization; acute [24 h]
tent thrombosis) in the absence of concomitant platelet
P IIb/IIIa receptor blockade. Indeed, higher levels of
eri-procedural platelet inhibition are achieved by the
ombination of aspirin, clopidogrel, and GP IIb/IIIa
nhibition compared with aspirin and clopidogrel alone in
he context of either UFH or bivalirudin anticoagulation
31,89,90).
ew Therapeutic Options
he limitations of currently available thienopyridines (ticlo-
idine, clopidogrel) include delayed onset of action, irre-
ersibility, response variability among individual patients,
nd overall modest levels of platelet inhibition. Several novel
2Y12 receptor inhibitors (both thienopyridine and non-
hienopyridine) are currently in clinical development and
ave pharmacologic properties that should overcome some,
f not all, of these limitations.
rasugrel
rasugrel (CS747) is a novel thienopyridine that is admin-
stered orally in an inactive state and must be metabolized by
ytochrome-P450–dependent pathways to generate an ac-
ive form that irreversibly binds to the P2Y12 receptor
91,92). Comparative (prasugrel vs. clopidogrel) studies
uggest that prasugrel provides more rapid and more potent
latelet inhibition with less interindividual variability in
esponse (93,94). Indeed, the vast majority of clopidogrel
onresponders are responsive to prasugrel (95). In a ran-
omized controlled trial comparing prasugrel and clopi-
ogrel in patients undergoing PCI, the JUMBO-TIMI 26
Joint Utilization of Medications to Block Platelets
ptimally–Thrombolysis In Myocardial Infarction) trial,
linical target vessel thrombotic events (composite occur-
ence of stent thrombosis and urgent repeat target vessel
evascularization) were reduced (0.6% vs. 2.4%, respectively)
y prasugrel and noncoronary bypass-related bleeding
vents were similar (96). The TRITON-TIMI 38 (Trial to
ssess Improvements in Therapeutic Outcomes by Opti-
izing Platelet Inhibition with Prasugrel–Thrombolysis in
yocardial Infarction) trial compared treatment with clo-
idogrel (300-mg load, 75 mg daily) versus prasugrel
60-mg load, 10 mg daily) in 13,608 patients with acute
oronary syndromes in whom PCI was planned (97,98).
rasugrel therapy was associated with a significant reductionn the primary efficacy end point of the trial (cardiovascular
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117eath, nonfatal myocardial infarction, or nonfatal stroke)
rom 12.1% (clopidogrel) to 9.9% (prasugrel; p  0.001).
urthermore, significant reductions in urgent target vessel
evascularization (by 34%), myocardial infarction (by 24%),
nd stent thrombosis (by 52%) were observed following
rasugrel therapy. The greater efficacy of prasugrel, which
ccompanied the higher level of platelet inhibition achieved
y this agent, was associated with an increased incidence of
ife-threatening (1.4% vs. 0.9%) and fatal (0.4% vs. 0.1%)
leeding events compared with clopidogrel. The observation
f no net clinical benefit (composite of efficacy and safety
nd points) for prasugrel in patients 75 years of age or
60 kg weight should prompt efforts at dose modifica-
ion in these subgroups. Patients with prior stroke or
ransient ischemic attacks demonstrated net clinical ben-
fit from clopidogrel (vs. prasugrel) (98). Finally, in the
RINCIPLE-TIMI 44 (Prasugrel in Comparison to
lopidogrel for Inhibition of Platelet Activation and
ggregation–Thrombolysis In Myocardial Infarction)
rial, prasugrel (60-mg load; 10 mg daily) resulted in greater
latelet inhibition than was observed following high-dose
lopidogrel (600-mg load, 150 mg daily) in patients under-
oing catheterization with planned PCI (99).
ZD 6140
he AZD 6140 is a novel cyclo-pentyl-triazolo pyrimidine
onthienopyridine agent that acts directly (requires no
etabolic activation) and provides very rapid, reversible, and
otent P2Y12 receptor inhibition (91,100,101). The plasma
alf-life of AZD 6140 is approximately 12 h and thus
equires twice-daily dose administration (101). In the
ISPERSE-2 (Dose Confirmation Study Assessing anti-
latelet Effects of AZD6140 versus Clopidogrel in
STEMI) randomized comparative trial of AZD 6140
ersus clopidogrel in patients presenting with acute coronary
yndromes, myocardial infarction was less frequent in pa-
ients receiving AZD 6140 and major or minor bleeding
vents were similar (102). In the platelet function substudy
f DISPERSE-2, AZD 6140 provided a greater magnitude
f platelet inhibition with less interindividual variability
han was observed with clopidogrel (103).
angrelor
angrelor (formerly ARC 69931 MX) is a nonthienopyri-
ine, parenterally administered, direct-acting P2Y12 recep-
or antagonist that provides dose-dependent, reversible
nhibition. At high doses, cangrelor achieves nearly 100%
nhibition of ADP-induced aggregation with very limited
nterindividual variability in response (104,105). The
lasma half-life of cangrelor is approximately 3.3 min, and
latelet function returns to normal rapidly (60 min)
ollowing termination of intravenous infusion (105). No iifferences in bleeding event rates were observed in a
andomized comparison with placebo in patients undergo-
ng PCI (106). The pharmacologic properties of rapid onset
nd offset may be particularly advantageous for use in
atients presenting with acute coronary syndromes and
igh-risk predictors (positive biomarkers, ST-segment
hift) in whom early angiography with revascularization is
onsidered. Indeed, controversy surrounds the potential for
linical benefit provided by P2Y12 receptor inhibitor pre-
reatment (clopidogrel) prior to PCI and the concern for
leeding associated with irreversible drug effect if surgical
oronary revascularization is required based on coronary
natomic considerations. Cangrelor is currently undergoing
linical evaluation in the CHAMPION (Cangrelor versus
tandard tHerapy to Achieve optimal Management of
latelet InhibitiON PCI) trial (107).
rotease-Activated Receptor (PAR)-1 Inhibition
he PAR-1 is present on platelets, smooth muscle cells,
onocytes/macrophages from human atheroma tissue, and
t lesion sites following percutaneous interventions (108).
here has been a great recent interest in the development of
AR-1 antagonists as potential antithrombotic agents. Oral
AR-1 antagonists may provide several advantages over
hrombin inhibitors in specifically inhibiting the PAR-1
eceptor and having no influence on the enzymatic effect of
hrombin in the coagulation cascade, the generation of the
brin network, or the stimulation of anticoagulant pathways
activation of protein C). These attributes make PAR-1
ntagonism a unique antithrombotic target with potential
imited bleeding side effects (108).
The SCH-530348 drug has been demonstrated to be a
pecific, potent, and reversible PAR-1 antagonist with a
ong half-life and no apparent effect on bleeding or clotting
imes or other receptor signaling pathways in platelets. In a
ecently completed randomized, double-blind, placebo-
ontrolled, dose-ranging Phase 2 study (TRA-PCI
Thrombin Receptor Antagonist–Percutaneous Coronary
ntervention] study), 1,030 patients undergoing coronary
ngiography and/or nonemergent PCI were treated with
oading doses of 10, 20, or 40 mg of SCH-530348 together
ith aspirin, clopidogrel, and an antithrombotic agent
heparin or direct thrombin inhibitor) (109). Following
CI, maintenance doses of 0.5, 1, or 2.5 mg were admin-
stered for 60 days along with aspirin and clopidogrel.
reatment with SCH-530348 was not associated with a
ignificant increase in the trial primary end point (TIMI
ajor or minor bleeding), although slight reductions in the
econdary end points of MACE (by 32%) and myocardial
nfarction (by 41%) were observed. In a substudy, SCH-
30348 did not affect arachidonic acid-, ADP-, or collagen-
nduced platelet aggregation, but was associated with80%
nhibition of 15-mmol/l thrombin receptor-activating
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118eptide–induced platelet aggregation at both the 1- and
.5-mg maintenance doses. The results from the TRA-PCI
tudy have provided the rationale for 2 large-scale multina-
ional, randomized, double-blind, placebo-controlled phase
 studies (TRA 2P-TIMI 50 [Thrombin Receptor Antag-
nist in Secondary Prevention of Atherothrombotic Events–
hrombolysis In Myocardial Infarction] and TRA-ACS
Thrombin Receptor Antagonist in Acute Coronary Syn-
rome] trials).
onclusions
he level of pre-procedural platelet reactivity correlates
irectly with both the level of post-procedural (and post-
reatment) platelet reactivity as well as the incidence of
eri-procedural adverse clinical outcomes (MACE). The
ntensity of peri-procedural platelet inhibition by adjunctive
harmacotherapies has been inversely correlated with the
ccurrence of peri-procedural MACE. These observations
ave validated the concept of targeting high levels of
eri-procedural platelet inhibition during PCI. Recent data
upport a direct relationship between the post-PCI and
ost-pharmacotherapeutic treatment level of platelet reac-
ivity and the subsequent occurrence of ischemic events,
ncluding both early and late stent thrombosis. In fact,
reliminary evidence supports the concept of a threshold for
ost-treatment platelet reactivity. Those patients who dem-
nstrate 50% residual platelet aggregation in response to
0-mol/l ADP appear to have the best long-term clinical
utcomes. However, the timing and method of measuring
latelet function that best correlates with subsequent patient
utcomes remains under investigation. Conversely, the re-
ationship of bleeding events to specific levels of residual
DP-induced platelet aggregation is unknown. Consid-
rable interindividual variability in platelet inhibitory
esponse exists to currently available antiplatelet thera-
ies. The prevalence of aspirin and/or clopidogrel resis-
ance is dependent on the definitions employed (clinical
vents vs. pharmacodynamic testing) as well as the
pecific test methodology (type and strength of agonist,
pecific threshold definition of hyporesponsiveness). Al-
hough the prevalence of either aspirin or clopidogrel
esistance may be reduced by increasing the dose of
edication, it cannot be eliminated, and interindividual
ariability in response persists. Ongoing large-scale clin-
cal trials will better define the relationship between ex
ivo platelet inhibition by specific therapeutic agents and
he degree of clinical benefit conferred by treatment.
opefully, these studies will also help to script the
ppropriate therapeutic algorithm for response in those
atients determined to be at high risk for adverse clinical
vents based on measurement of platelet reactivity. Finally,
he advent of direct-acting antithrombin agents for peri-
rocedural anticoagulation coupled with novel antiplateletherapies on the immediate horizon promise to enhance the
afety and efficacy of peri-procedural adjunctive pharmaco-
herapy and to improve late clinical outcomes following
CI.
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